In a comparison between pancreatic cancer patients in stages I–IV, healthy individuals, and patients with benign pancreatic disease (BPD), the ROC curves showed that GPC1+ crExos acted as an almost perfect classifier, achieving an AUC of 1.0 (95% CI, 0.988–1.0). This evidence concerns the gene GPC1 and familial pancreatic carcinoma.